












































Angiogenesis is a key event in the progression of 
malignant gliomas [1,2].  It is a highly regulated process 
that involves a complex cascade of events.  Because of 
the physiological and pathological importance of 
angiogenesis in glioblastoma, extensive research has 
been carried out to identify the factors that regulate this 
process. The expression of angiogenic factors by tumor 
cells promotes the establishment of a  tumor vasculature  
 
 











































that facilitates tumor growth.  Vascular endothelial 
growth factor (VEGF) is the most potent growth factor 
implicated in the signaling pathway of glioma 
angiogenesis in that it promotes proliferation and 
migration of endothelial cells [3].  Focal adhesion 
kinase (FAK) is a cytoplasmic tyrosine kinase, which is 
involved in early integrin signaling and has been shown 
to regulate cell migration, proliferation, survival, and 
invasion in some cell types.  Integrin recognition of an 
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temporally related manner, the autophosphorylation of 
FAK on tyrosine 397 (activation), followed by the 
formation of focal adhesions at the submembranous 
region of the cell [4,5].  The ability of FAK to promote 
cell migration, proliferation, and invasion suggested that 
FAK could be necessary for endothelial cell sprouting 
and tube formation [6].  FAK influences the dynamic 
regulation of integrin-associated adhesions and the actin 
cytoskeleton that is tethered there through diverse 
molecular interactions.  This, in turn, regulates cell 
migration by controlling the focal-complex assembly/ 
disassembly cycle at the leading lamellipodia of 
migrating cells while also controlling adhesion 
disassembly at the trailing edge.  As these processes are 
crucial components of cell migration, and therefore also 
of invasion by cancer cells, FAK might well be 
involved in the spread of cancer cells [7].  Also, FAK 




































sels of malignant astrocytomas where it might 
contribute to angiogenesis by enabling haptotactic 
migration towards ECM proteins [6]. 
 
However, much more work needs to be done to fully 
determine the role of FAK in tumorigenesis, which 
might vary in different tumor types.  The causal role of 
FAK in tumor development combined with reports that 
increased FAK expression is associated with poor 
clinical outcome [8,9] indicates that FAK might be a 
useful therapeutic target [7,10].  In the present study, we 
studied the effect of human umbilical cord blood-
derived mesenchymal stem cells (hUCBSC) on the role 
of FAK and its related molecules in glioma cells in vitro 
and in vivo.  We observed that hUCBSC downregulate 
FAK and its related molecules in both in vitro and in 
vivo conditions, thereby disrupting the process of 








































collected  from  the  glioma  cells  treated  either  with  FAK  inhibitor  (10μM  for  1.5h)  or
transfected with siFAK.  Conditioned medium was added to HMEC cells pre‐seeded (5000
cells/well)  in  96‐well  plates.  After  72h  of  incubation,  HMEC  cells  were  observed  for
capillary‐like network formation and photographed under a light microscope.  
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Inhibition of angiogenesis by conditioned media of 
hUCBSC 
 
To evaluate the effect of hUCBSC on glioma 
angiogenesis, we co-cultured glioma cells with 
hUCBSC for 72h.  The conditioned medium from both 
single and co-cultures were collected and HMEC cells 
were grown in these conditioned media.  The process of 
vessel formation was observed for 24 to 48h after the 
addition of conditioned media.  All the HMEC cells 
grown in glioma conditioned media showed extensive 
vessel formation after 48h.  On the other hand, HMEC 
cells grown in co-culture media showed disorganized 
vessel formation or no vessel formation (Figure 1).  To 
evaluate the mechanism of action of hUCBSC, we 
repeated the experiment with FAK inhibitor and siRNA 
to FAK (siFAK). In both the experiments, vessel 
formation by HMEC cells was highly disorganized 
compared to control glioma cells conditioned media. 
These results confirm that hUCBSC are acting by a 
mechanism similar to FAK inhibitor or siFAK.  This 































regulate FAK in order to inhibit angiogenesis of glioma 
cells. To determine the effect of hUCBSC on the 
proteins involved in angiogenesis, we ran immunoblot 
analysis of lysates from single and co-cultures of glioma 
cells.  FAK, pFAK, Akt and pAkt showed reduced 
expression in co-cultures (Figure 2A).  Further, we 
tested the effect of hUCBSC on ERK1/2, pERK1/2.  We 
observed that both these molecules were down-regulated 
by hUCBSC treatments in co-cultures. We also tested the 
signaling molecule VEGF involved in angiogenesis and 
observed that stem cells decreased the expression of 
VEGF in glioma cells.  These results prove that hUCBSC 
are able to downregulate proteins involved in 
angiogenesis, thereby preventing vessel formation. 
Similar to these results, transcriptional status of the 
molecules FAK, VEGF and VEGFR1 were also 
downregulated by hUCBSC (Figure 2B). In order to 
evaluate the specific effect of hUCBSC on glioma cells, 
we co-cultured glioma cells with human lung fibroblasts 
for 72h and ran immunoblot analyses for the above 
proteins. Fibroblasts did not show any effect on glioma 
cells in controlling their angiogenic proteins (Figure 2C). 
These results confirm that hUCBSC alone are effective in 















































































FAK is a widely expressed cytoplasmic protein tyrosine 
kinase involved in integrin-mediated signal transduction 
and plays an important role in the control of several 
biological processes, including cell spreading, 
migration, survival and angiogenesis.  We evaluated the 
expression of FAK by immunofluorescence and 
observed that hUCBSC inhibited the expression of FAK 
(Figure 3A).  In co-cultures of glioma cells, the number 
of cells expressing FAK was very low as compared to 
control cells.  Also, FACS analysis of single and co-
cultures of glioma cells revealed that FAK expression 
was significantly inhibited by hUCBSC treatment 
(Figure 3B).  This downregulation was significantly 










































and 5310 co-cultures.   Since FAK is associated with 
integrin signaling, we tested the expression of integrin 
αvβ3 in glioma cells and their co-cultures.  Similar to 
FAK expression, hUCBSC inhibited the expression of 
αvβ3 in co-cultures (Figure 3C).  Quantitative analysis 
revealed that SNB19 had a lower percentage of cells 
expressing  αvβ3  followed by 5310 and U251 (Figure 
3D).  To confirm these results, we isolated total RNA 
from single and co-cultures of glioma cells with 
hUCBSC and converted it into cDNA.  We ran cDNA 
microarrays to test the array of genes related to angio-
genesis that were affected by hUCBSC treatment.  Most 
of the genes involved in angiogenesis were down-























































1). In particular, Ang1 and Ang2 genes were down-
regulated apart from the growth factors EGF, FGF2, 
IGF1, PDGF-A and VEGF-A.  This is associated with 
downregulation of Akt. These results confirm that 
hUCBSC influence a wide array of genes involved in 
angiogenesis, thereby controlling the growth of glioma 
cells.  
 
Downregulation of FAK by hUCBSC treatment has 
an anti-angiogenic effect in U251 and 5310 glioma 
nude mice models 
 
Our  in vitro experiments have proven that co-culture 
with hUCBSC can efficiently inhibit glioma 









































in angiogenesis.  Therefore, we investigated the anti-
angiogenic effect of these stem cells in vivo using U251 
and 5310 cells in nude mice.  For this, we implanted 
U251 and 5310 cells into the right side of the brains of 
nude mice by intracranial administration as explained in 
Materials and Methods.  After 7 days, hUCBSC were 
administered in a similar way but towards the left side 
of the brain.  After the mice were implanted with U251, 
5310 and hUCBSC, the mice were observed for 21 
days.  At that point, tumor samples were taken, and 
paraffin-embedded sections were prepared for 
immunohistopathological examination.  Hematoxylin 
and Eosin (H&E) staining of the in vivo sections clearly 
showed that the tumors in hUCBSC-treated mice were 
inhibited significantly and were one-third the size of the 
Table 1. Effect of hUCBSC treatment on the expression of angiogenic molecules in glioma cells 
 
Genes  Description  Fold  difference   
SNB19            U251             5310   
AKT1  V-akt murine thymoma viral oncogene homolog 1  -1.32  -30.48  -1.24 
ANG1  Angiopoietin  1  -3.36 -1.34 -2.28 
ANG2 Angiopoietin  2  -1.33  -1.97 
 
-6.02 
EGF Epidermal  growth  factor -1.68  -24.76 
 
-3.23 
FGF2  Fibroblast growth factor 2   -1.19  -11.96  -1.56 
IGF1  Insulin-like growth factor 1  -2.00  1.59  -3.12 
MMP-2 Matrix  metallopeptidase  2  -3.36  -27.47  -2.81 
MMP-9 Matrix  metallopeptidase  9  4389  10.7  317.37 
PDGF-A  Platelet-derived growth factor alpha polypeptide  -1.32  -5.78  1.01 
TGFB1  Transforming growth factor, beta 1  1.23  -19.43  1.47 
THBS1 Thrombospondin  1  -1.37  -22.32  2.23 
THBS2 Thrombospondin  2  -2.22  -5.39  -3.71 
TIMP-1  TIMP metallopeptidase inhibitor 1  1.11  -15.78  -1.03 
TIMP-2  TIMP metallopeptidase inhibitor 2  -1.15  -20.11  1.69 
TIMP-3  TIMP metallopeptidase inhibitor 3  -2.31  4.99  2.85 
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checked for the presence of hUCBSC in the nude mice 
brains using mesenchymal stem cell markers CD29 by 
immunofluorescence.  Control tumor sections did not 
show the expression of CD29. CD29
+ cells were 
present only in the hUCBSC-treated brain sections, 
which confirm the presence of stem cells in the treated 
brains (Figure 4B).  Further, we performed the dorsal 
skin fold chamber assay by introducing U251 and 
5310 cells below the skin folds of athymic nude mice.  
In a similar fashion, co-cultures of both these cells 
with hUCBSC were also introduced below the skin 
folds of nude mice.  The mice were euthanized after 14 
days, and the skins were removed and observed under 
a bright field microscope.  Extensive vessel formation 
was observed in the skins of mice treated with U251 
and 5310 cells whereas skins having co-cultures of 
glioma cells with hUCBSC did not show vessel 
formation (Figure 5A).  This in vivo assay proves that 



































We also checked the expression of FAK in the control 
tumor and hUCBSC-treated tumor sections.  For this, 
we did co-localization experiments with CD81 (mesen-
chymal stem cell marker) and FAK antibody.  FAK was 
highly expressed in the control tumor brains as 
compared to hUCBSC-treated brain sections, which 
showed high expression of CD81 (Figure 5B). We then 
checked the expression of CD31 or PECAM-1 (Platelet 
Endothelial Cell Adhesion Molecule-1) in both control 
tumors of hUCBSC-treated mice brain sections. DAB 
immunohistochemistry revealed that CD31 was highly 
expressed in both U251 and 5310 control tumor brains, 
whereas in hUCBSC-treated mice brains, expression of 
CD31 was almost negligible (Figure 5C).  Next, we 
checked for expression of VEGF in the brain sections.  
Control tumor sections showed high expression of 
VEGF in the tumor areas, whereas in hUCBSC-treated 
tumors, very low level of expression of VEGF was 
observed (Figure 5D).  These results confirm that FAK 
and VEGF expression were highly downregulated in 









































administration,  the  brains  were  harvested,  sectioned  and  immunoprobed  with  mesenchymal  stem  cell
markers CD29 using Alexa fluor‐594 secondary antibody.  (n = 3). Scale bar = 100μm.  
   












































To evaluate the mechanism by which angiogenesis is 
inhibited in the nude mice tumor brains, we analyzed 
the tissue lysates by immunoblot analysis and observed 
that FAK was downregulated in tissue lysates of 
hUCBSC treatments.  Then, we analyzed different 




925). In hUCBSC-treated mice brains, 
downregulation of FAK and pFAK at Tyr
397 was 
significant (Figure 6B).  Out of all these phospho-forms 
of FAK, only pFAK (Tyr
397) was significantly down-













































change in other phospho forms.  This indicates that 
hUCBSC are targeting the phosphorylation of Tyr
397 
(Figure 6A). Other proteins that are involved in 
angiogenesis including ERK1/2, pERK1/2, Akt and 
pAkt were also downregulated in the hUCBSC 
treatments (Figure 6C).  Quantification confirmed that 
these molecules were downregulated in tumor brains 
treated with hUCBSC (Figure 6D).  Similar to our in 
vitro results VEGF, Tie2 and Ang1 were also 
downregulated under in vivo conditions (Figure 6E). 








were  recorded  as  tumor‐induced  neovascularization.  These  branches  were  then  compared  to  the  more
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6F).  Finally, we evaluated the molecules that are 
involved in the process of angiogenesis by reverse-
transcription based PCR.  Growth factors VEGF, 
VEGFR1 along with FAK, Tie2 and Ang1 showed 
reduced expression, confirming that the process of 
















































level (Figure 6G).  These results confirm that 
downregulation of FAK in mice tumor brains induces 
the downregulation of integrins as well as growth 
factors necessary for angiogenesis.  Taken together, 
these results confirm the anti-angiogenic effect of 
hUCBSC  in vivo and that tumor cell angiogenesis in 
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Tumor angiogenesis, which is necessary for tumor cell 
invasion and proliferation, indicates an aggressive phase 
in tumor biology and typically correlates with increased 
tumor growth and metastasis [11].  Among all solid 
tumors, glioblastoma multiforme (GBM) has been 
reported to be the most angiogenic and displays the 
highest degree of vascular proliferation and endothelial 
cell hyperplasia [12].  Due to angiogenesis, the glioma 
vessel structure is markedly abnormal, resulting in 
decreased delivery of chemotherapies, increasing tumor 
hypoxia, and producing edema with its clinical 
consequences [13].  Targeting angiogenesis as a means 
of sensitizing gliomas to other treatment modalities has 
been adapted in recent times.  Hence, we targeted 
angiogenesis of glioblastoma cells using hUCBSC.  In 
our study, we observed that angiogenesis has been 
inhibited by hUCBSC in both in vitro as well as in vivo 
conditions.  Our results provide hope that hUCBSC 
could become potential therapeutic tools to treat glio-
blastoma. 
 
Focal adhesion kinase (FAK) is an important mediator 
of growth factor signaling, cell proliferation, cell 
survival and cell migration.  FAK resides at sites of 
integrin clustering—the so-called focal adhesions—that 
are prominent in cells grown in tissue culture [7].  FAK 
controls the dynamic regulation of integrin-linked 
adhesions, cadherin dependent cell–cell adhesions and 
peripheral actin structures, and so contributes to cell 
migration and invasion [5,14,15].   However, the causal 
role of FAK in tumor development combined with 
reports that increased FAK expression is associated 
with poor clinical outcome [8,9], indicate that FAK 
might be a useful therapeutic target [7,10].  
 
FAK is overexpressed in invasive and metastatic tumors 
[16], and the FAK gene is also amplified in many types 
of tumors [17] suggesting a role for FAK in adhesion or 
survival in tumor cells.  In cancer cells, attenuation of 
FAK expression induces detachment and apoptosis [18] 
suggesting that a FAK-dependent signal is required for 
tumor cell growth. We have previously shown that 
hUCBSC induces apoptosis in glioma cells [19] and 
upregulates PTEN in order to control their growth and 
proliferation [20]. In the present study, we also 
observed that downregulation of FAK resulted in 
decreased tumor growth in hUCBSC-treated tumors in 
mice brains.  Here, we provide evidence suggesting that 
FAK promotes angiogenesis in malignant glioblastoma 
and hUCBSC downregulated FAK, thereby inhibiting 
vessel formation.  We found an elevated expression of 
FAK in the glioma cells, which was highly down-
regulated by hUCBSC in the co-cultures.  Furthermore, 
when these studies were repeated on brain tumors from 
an intracerebral nude mouse xenograft model of 
malignant glioblastoma, FAK and pFAK were detected 
at increased levels in the tumors as compared to the 
hUCBSC-treated brain tumors.  These results suggest 
that hUCBSC regulate FAK levels (both normal as well 
as phosphorylated forms), and as such, hUCBSC could 
be used for the treatment of glioblastoma. 
 
Integrins are transmembrane receptor molecules that are 
responsible for the interaction of endothelial and tumor 
cells with the ECM.  Integrin signal transduction 
mediates endothelial cell migration and invasion [21].  
The most common molecules allowing glioma cells to 
adhere to the ECM are integrins, particularly the 
integrin αvβ3, which binds fibronectin in the ECM. In 
our study, we observed that αvβ3 is highly expressed in 
both  in vitro as well as in vivo conditions (data not 
shown).  Since hUCBSC were able to inhibit the 
expression of FAK, expression of αvβ3  was also 
downregulated to significant levels both at transcription 
as well as translational levels.  The downregulation of 
these molecules along with reduced expression of Akt 
and pAkt abolished the process of angiogenesis in 
tumors in the present study.  Furthermore, the ability of 
tumor cells to migrate is demonstrated to be associated 
with increased FAK expression.  The expression of 
FAK in human malig-nant astrocytic tumor cells 
increased their migration [22].  In contrast, inhibiting 
FAK expression and signaling reduced motility of 
adenocarcinoma cells [23].  The activation of 
endogenous EphA2 by ephrin-A1 was also found to 
suppress the activity of FAK and integrins [24], and 
thus inhibits integrin-mediated cell migration. Our 
results provide evidence that downregulation of FAK 
and phosphorylated FAK by hUCBSC resulted in 
decrease in the expression of VEGF which resulted in 
the attenuated migration of U251 and 5310 cells, and 
hence regression of tumor growth in vivo. 
 
In normal brain tissue there is very little or no 
expression of VEGF and its receptor VEGFR-1.  On the 
other hand, VEGF/VEGFR-1 is highly expressed in 
high-grade glioblastoma. Blocking or obstructing the 
VEGF/VEGFR signal transduction pathway by different 
methods can prevent the vascularization, metastasis, and 
edema of animal transplanted tumors and result in 
restricted tumor growth [25,26]. In the present study, 
there was expression of VEGF protein in glioma cells as 
well as each xenograft model of nude mice.  hUCBSC 
could suppress the expression of VEGF and VEGF-A 
proteins in transplanted tumors in nude mice.  We 
concluded that hUCBSC can lower the expression of 
receptor proteins VEGFR-1 and VEGFR-2 and weaken 
the signal transduction of VEGF.  This can remarkably 
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suppressing vessel formation.  
 
We found that hUCBSC exhibit anti-angiogenic and 
anti-tumor activities both in vitro and in vivo.  Our 
study shows that hUCBSC had the following key 
functions: (1) hUCBSC inhibited tube formation in 
vitro; (2) hUCBSC inhibited the development of new 
vessels in the dorsal skin fold chamber assay; and (3) 
hUCBSC inhibited the tumor growth induced by glioma 
cells.  Moreover, hUCBSC inhibited the expression of 
FAK and related angiogenic molecules in the 
xenografts.  In conclusion, our data suggest that FAK 
promotes angiogenesis in malignant glioblastoma 
tumors and that the mechanism by which FAK 
promotes angiogenesis involves integrin αvβ3; hUCBSC 
were able to downregulate FAK and αvβ3 as well as 
other signaling molecules involved in this process.   
Hence, hUCBSC could potentially be a useful 
therapeutic tool for the treatment of patients with 
glioblastoma. 
 
MATERIALS AND METHODS 
 
Ethics Statement.  After obtaining informed consent, 
human umbilical cord blood was collected from healthy 
volunteers according to a protocol approved by the 
Peoria Institutional Review Board, Peoria, IL, USA.     
The consent was written and approved. The approved 
protocol number is 06-014, dated December 10, 2009.   
The Institutional Animal Care and Use Committee of 
the University Of Illinois College Of Medicine at 
Peoria, Peoria, IL, USA approved all surgical 
interventions and post-operative animal care.  The 
consent was written and approved. The approved 
protocol number is 851, dated November 20, 2009. 
 
Cell Cultures.  Two high-grade human glioma cell lines 
(SNB19 and U251) and a xenograft cell line (5310) 
were used for this study.  SNB19 and U251 cells were 
obtained from ATCC.  The xenograft cell line (5310) 
was kindly provided by Dr. David James at the 
University of California San Francisco.  SNB19 and 
U251 cells were grown in Dulbecco’s modified Eagle 
medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS) and 1% penicillin-streptomycin.  5310 
cells were grown in RPMI 1640 medium supplemented 
with 10% FBS and 1% penicillin-streptomycin. After 
obtaining informed consent, human umbilical cord 
blood was collected from healthy volunteers according 
to a protocol approved by the Institutional Review 
Board.  Human umbilical cord blood was enriched by 
sequential Ficoll density gradient purification.  Next, we 
selected cells using  CD29
+  and CD81
+  markers as 
described previously [27]. The nucleated cells were 
suspended at a concentration of 1×10
6/μL in Knockout 
DMEM (Invitrogen) supplemented with 10% FBS, 10% 
Knockout serum replacement (Invitrogen) and 1% 
penicillin-streptomycin and plated in 100-mm culture 
dishes.  For co-culture experiments, hUCBSC and 
glioma cells were cultured at a ratio of 1:4. Co-cultures 
of hUCBSC and SNB19, hUCBSC and U251 were 
grown in DMEM; co-cultures of hUCBSC and 5310 
were grown in RPMI-1640. Primary cultures of human 
lung fibroblasts were obtained from ATCC and were 
grown in DMEM supplemented with 10% FBS and 1% 
penicillin-streptomycin. Co-cultures of fibroblasts and 
SNB19, fibroblasts and U251 were grown in DMEM; 
co-cultures of fibroblasts and 5310 were grown in 
RPMI-1640.Cultures were maintained at 37°C in a 
humidified 5% CO2 atmosphere. In all experiments co-
cultures were grown for 72h. Cultures were fed every 3 
days with fresh medium.  
 
In vitro angiogenesis assay.  The endothelial tube-like 
formation assay was performed as described previously 
[28].  Matrigel was plated into flat-bottomed 96-well 
tissue culture plates and then incubated at 37
oC for 
20min to allow the Matrigel to polymerize. Human 
microvascular endothelial cells (HMEC) were seeded in 
the matrigel-coated plates. After cells adhered to the 
wells (12h), growth medium was replaced by 
conditioned medium.  Conditioned medium from 
SNB19, U251 and 5310 control and hUCBSC-treated 
glioma cells were added to HMEC cells.  After 48h in 
the treated media, dead floating cells were washed away 
and the cells showing angiogenesis were stained by 
Hema-3 stain.  We quantified tube formation by 
measuring the number of branch points and the total 
number of branches per point in triplicate wells. 
 
Dorsal skin fold chamber model.  Tumor angiogenesis 
was quantified in vivo using the transparent dorsal skin 
fold chamber model [29].  Briefly, after total body 
anesthesia with ketamine (50mg/kg) and xylazine 
(5mg/kg), a dorsal air sac was made in the mouse by 
injecting 5 mL of air. After dorsal skin fold preparation, 
chambers were inoculated with 2×10
6 glioma cells or 
co-cultures of glioma cells and hUCBSC.  14 days later, 
the animals were anesthetized and sacrificed.  The 
animals were carefully skinned around the implanted 
chambers, and the implanted chambers were removed 
from the subcutaneous air fascia.  The skin fold 
covering the chambers was photographed under visible 
light.  The number of blood vessels within the chamber 
in the area of the air sac fascia was counted, and their 
lengths were measured. 
 
Immunocytochemistry.  Cultured hUCBSC were 
checked for mesenchymal markers by immuno-
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slides were rinsed twice with phosphate buffered saline 
(PBS) and fixed in 4% paraformaldehyde.  After 
additional PBS rinses, cells were blocked with 10% 
goat serum for 1h.  Primary antibodies (1:100 dilutions) 
specific for mesenchymal markers [mouse anti-CD29 
(Millipore), goat anti-CD81 (Santa Cruz)] were diluted 
in goat serum and applied overnight at 4
oC.  Texas Red 
conjugated anti-mouse or anti-rabbit secondary 
antibodies were diluted (1:200) in goat serum and 
applied individually for 1 to 2h at room temperature.   
Before mounting, the cells were stained with 4', 6-
diamidino-2-phenylindole (DAPI).  In a similar manner 
single and co-cultures of glioma cells in 8-well chamber 
slides were processed with FAK and αvβ3 antibodies. 
The cells were observed using a fluorescence 
microscope (Olympus IX71, Melville, NY) and/or a 
confocal microscope (Olympus Fluoview) and 
photographed. 
 
Construction of shRNA-expressing plasmid and 
transfection of siFAK.  For this study, pSilencer™ 4.1-
CMV plasmid vector (Ambion, Austin, TX) was used in 
the construction of the shRNA-expressing vector. The 
human FAK target sequence AAGCCTTAACAATGC 
GTCAGTTT  was used for the siRNA sequence. 
Inverted repeat sequences were synthesized for FAK.   
The inverted repeats were laterally symmetrical making 
them self-complimentary with a 9-bp mismatch in the 
loop region. This 9-bp mismatch would aid in the loop 
formation of the shRNA. Oligonucleotides were heated 
in a boiling water bath in 6X SSC for 5 min and self-
annealed by slow cooling to room temperature. The 
resulting annealed oligonucleotides were ligated to 
pSilencer at the BamHI and HindIII sites. For 
transfection, the cancer cells were cultured as 
mentioned previously.  Cells at 60-70% confluency in 
100mm tissue culture plates were transfected with 10μg 
of siRNA-expressing plasmid constructs (siFAK) using 
Fugene HD as per manufacturer’s instructions (Roche).  
 
RNA extraction and quantitative real time PCR.  All 
primer sequences were determined using established 
human GenBank sequences and designed using Primer3 
software (v.0.4.0).  For real time polymerase chain 
reaction (RT-PCR) analysis and RT-PCR-based micro-
array analysis (SA Biosciences, Frederick, MD), total 
RNA was isolated from control and hUCBSC-treated 
glioma cells and reverse transcribed into first strand 
cDNA.  PCR amplification was performed using primer 
sets and amplified by 35 cycles (94
oC, 1 min; 60
oC, 1 
min; 72
oC, 1 min) of PCR using 20 pM of specific 
primers.  Further quantitative analysis of genes was 
done by SYBR green based real-time PCR using Bio-
Rad iCycler iQ Real-Time PCR Detection System.   
Each sample was measured in triplicate and normalized 
to the reference GAPDH or β-actin gene expression.   
Delta CT (ΔCT) and ΔΔCT values were calculated and 
the fold change in the test gene expression was finally 
calculated.  A statistical evaluation of real-time PCR 
results was performed using one-way analysis of 
variance (ANOVA) to compare test gene expression 
between cancer cells and their co-cultures with 
hUCBSC.  
 
Primers used for PCR. 
FAK Sense  5’ggtgcaatggagcgagtatt3’ 
 Antisense  5’gccagtgaacctcctctga3’ 
VEGF Sense  5'ctacctccaccatgccaagt3' 
 Antisense  5'cacacaggatggcttgaaga3' 
VEGFR1 Sense  5’gttcaaggaacctcggacaa3’ 
 Antisense  5’gctcacactgctcatccaaa3’ 
Tie2 Sense  5'gttcacaagccttctcacacg3' 
 Antisense  5'gttcacaagccttctcacacg3' 
Ang1 Sense  5'acgatggcaactgtcgtgag3' 
 Antisense  5'tccgacttcatgtttccacaa3' 
β-Actin  Sense 5’gtcgtaccactggcattgt3’ 
 Antisense  5’cagctgtggtggtgaagct3’ 
 
cDNA microarray analysis.  W e  u s e d  h u m a n  
Angiogenesis PCR array (SA Biosciences) because of 
its advantage of real-time PCR performance combined 
with the ability of microarrays to detect the expression 
of many genes simultaneously.  Real time PCR was 
carried out under the following conditions: one cycle of 
95
oC for 10 min, 40 cycles of 95
oC for 15 sec and 60
oC 
for 1 min.  Changes in gene expression were illustrated 
as a fold increase/decrease according to manufacturer’s 
instructions.  The cut-off induction determining 
expression was 2.0 or –2.0 fold changes. Genes that met 
these criteria were considered to be upregulated or 
downregulated.  We performed these experiments in 
duplicate. 
 
Immunoblot analysis.  Single and co-cultures of glioma 
cells or nude mice brain tissues were harvested and 
homogenized in four volumes of homogenization buffer 
and processed for cell lysates as described previously 
[27].  Samples (40µg of total protein) were subjected to 
8-14% SDS-PAGE and transferred onto nitrocellulose 
membranes.  The reaction was detected using 
Hyperfilm-MP autoradiography film (Amersham, 
Piscataway, NJ).  The following antibodies were used 
for Western blot analysis: mouse anti-FAK  (1:200; 
Santa Cruz Biotechnology, Santa Cruz, CA), mouse 
anti-pFAK and all other pFAK antibodies (1:500; Santa 
Cruz), goat integrin αvβ3 (1:500; Santa Cruz), mouse 
anti-ERK (1:5000; BD Biosciences, Franklin Lakes, 
NJ), rabbit anti-AKT (1:1000; Cell Signaling), mouse 
anti-Ang1 (1:1000; Cell Signaling), rabbit anti-VEGF 
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71) antibody (1:1000; Cell 
Signaling], and mouse anti-Tie2 (1:1000; BD 
Biosciences).    Immunoblots were stripped and redeve-
loped with GAPDH antibody [mouse anti-GAPDH 
(1:1000; Santa Cruz)]  to ensure equal loading levels.   
Experiments were performed in triplicate.  Values for 
treated and untreated samples were compared using 
one-way ANOVA.  A p value of <0.05 was considered 
significant. 
 
Intracranial tumor growth.  The Institutional Animal 
Care and Use Committee of the University Of Illinois 
College Of Medicine at Peoria approved all surgical 
interventions and post-operative animal care.   U251 
(1×10
6 cells) and 5310 (8×10
5 cells) tumor cells were 
intracerebrally injected into the right side of the brains 
of nude mice, as described previously [30].  Seven days 
after tumor implantation, the mice were injected with 
hUCBSC near the left side of the brain.  The ratio of the 
hUCBSC to glioma cells was maintained at 1:4. Three 
weeks after tumor inoculation, six mice from each 
group were sacrificed by cardiac perfusion with 4% 
formaldehyde in PBS, their brains were removed, and 
paraffin sections were prepared.  Sections were stained 
with H&E to visualize tumor cells and to examine 
tumor volume.  The sections were blind reviewed by a 
neuropathologist and scored semiquantitatively for 
tumor size.  Whole-mount images of brains were also 
taken to determine infiltrative tumor morphology.  The 
average tumor area per section integrated to the number 
of sections where the tumor was visible was used to 
calculate tumor volume; tumor volumes were compared 
between controls and treated groups.  
 
Immunohistochemical analysis.  Brains of control and 
hUCBSC-treated mice brains were fixed in 
formaldehyde and embedded in paraffin as per standard 
protocols.  Sections were deparaffinized as per standard 
protocol.  After H&E staining, transmitted light images 
were obtained to visualize the morphology of the 
sections. For immunohistochemistry, sections were 
blocked in 10% goat serum for 1h, and were 
subsequently transferred to primary antibody diluted in 
10% goat serum (1:100) overnight at 4
oC in a 
humidified chamber. Sections were then washed in 1% 
BSA in PBS, incubated with the appropriate secondary 
antibody for 1h and visualized using a fluorescence 
microscope.    For immunofluorescence, sections were 
treated with primary antibodies overnight at 4
oC and 
then treated with appropriate Alexa fluor secondary 
antibodies at room temperature for 1h.  Negative 
controls were maintained either without primary 
antibody or using IgG.  
 
Statistical analyses.  Quantitative data from cell counts, 
Western blot analysis, and other assays were evaluated 
for statistical significance using one-way analysis of 
variance (ANOVA).  Data for each treatment group 
were represented as mean  ±  SE and compared with 
other groups for significance by one-way ANOVA 
followed by Bonferroni's post hoc test (multiple 
comparison tests) using Graph Pad Prism version 3.02, 
a statistical software package.  Results were considered 
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